Global Pulmonary Arterial Hypertension (PAH) Market to Reach USD 10.9 Billion by 2030; Growing Technological Advancements to Drive the Market | Markets N Research

The global pulmonary arterial hypertension (PAH) market is expected to exhibit strong growth, reaching USD 10.9 billion by 2030. As per the report titled "Pulmonary arterial hypertension (PAH) Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Endothelin Receptor Antagonists, SGC Stimulators, PDE-5 Inhibitors, Prostacyclin & Prostacyclin Analogs and Others), By Route of Administration (Oral, Intravenous/Subcutaneous and Others), By Type (Innovative and Generics), By Distribution Channel (Hospitals, Retail Pharmacies and Online Pharmacies), and Regional Forecasts, 2023-2030" observes that the market size in 2022 stood at USD 7.5 billion and USD 10.9 billion in 2030. The market is expected to exhibit a CAGR of 5.50% during the forecast period.

𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗳𝗼𝗿 𝗮 𝗦𝗮𝗺𝗽𝗹𝗲 𝗼𝗳 𝘁𝗵𝗶𝘀 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗥𝗲𝗽𝗼𝗿𝘁 @ https://marketsnresearch.com/sample/1651

𝐇𝐚𝐧𝐠𝐳𝐡𝐨𝐮 𝐂𝐡𝐚𝐧𝐜𝐞 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬 𝐂𝐨 𝐋𝐭𝐝 𝐀𝐧𝐝 𝐀𝐞𝐫𝐚𝐦𝐢 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬, 𝐈𝐧𝐜 𝐈𝐧𝐤𝐞𝐝 𝐀 𝐂𝐨𝐧𝐭𝐫𝐚𝐜𝐭 𝐅𝐨𝐫 𝐄𝐱𝐜𝐥𝐮𝐬𝐢𝐯𝐞 𝐋𝐢𝐜𝐞𝐧𝐜𝐢𝐧𝐠 𝐀𝐧𝐝 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 (𝐂𝐡𝐚𝐧𝐜𝐞)

In February 2021, Aerami Therapeutics, Inc. and Hangzhou Chance Pharmaceuticals Co. Ltd. (Chance) had an exclusive license and development agreement for the development and marketing of Aerami's drug-device combination product candidate ("AER-901") for the treatment of PAH in mainland China, Hong Kong, Macau, and Taiwan. According to the contract, Chance oversees the development and commercialization of AER-901 for PAH throughout the region.

𝐑𝐢𝐬𝐢𝐧𝐠 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐢𝐜𝐚𝐥 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐦𝐞𝐧𝐭𝐬 𝐭𝐨 𝐁𝐨𝐨𝐬𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐄𝐱𝐩𝐚𝐧𝐬𝐢𝐨𝐧

The pulmonary arterial hypertension market is seeing significant growth in major trends related to technological improvements. Companies in the pulmonary arterial hypertension drug industry are concentrating on creating new medications to treat and improve these conditions. For instance, the US-based biotechnology company United Therapeutics Corporation introduced Tyvaso for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease in April 2021. Patients who use Tyvaso improve their capacity for activity, ease breathing issues, have a low threshold for effort, and have a greater death risk.

𝐃𝐫𝐮𝐠 𝐒𝐢𝐝𝐞 𝐄𝐟𝐟𝐞𝐜𝐭𝐬 𝐀𝐧𝐝 𝐇𝐢𝐠𝐡 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐂𝐨𝐬𝐭𝐬 𝐅𝐨𝐫 𝐏𝐀𝐇𝐒 𝐀𝐫𝐞 𝐋𝐢𝐦𝐢𝐭𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭 𝐄𝐱𝐩𝐚𝐧𝐬𝐢𝐨𝐧

The FDA drug approval process is a drawn-out process that confirms the drug's efficacy and safety. Therefore, over the projected period, the expansion of the business may be constrained by a drawn-out regulatory process and negative impacts related to the use of PAH medications. Patients' ignorance about the frequency of pulmonary arterial hypertension, the discontinuation of drugs by major players during clinical trials, and the high costs of diagnosis and treatment are all expected to constrain the market.

𝐑𝐞𝐚𝐝 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰 𝐨𝐟 𝐑𝐞𝐩𝐨𝐫𝐭 @ https://marketsnresearch.com/report/1651/global-pulmonary-arterial-hypertension-pah-market

𝐌𝐚𝐣𝐨𝐫 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐃𝐞𝐯𝐞𝐥𝐨𝐩 𝐀𝐜𝐪𝐮𝐢𝐬𝐢𝐭𝐢𝐨𝐧 𝐏𝐥𝐚𝐧𝐬 𝐭𝐨 𝐁𝐨𝐨𝐬𝐭 𝐁𝐫𝐚𝐧𝐝 𝐈𝐦𝐚𝐠𝐞

The leading businesses in the pulmonary arterial hypertension (PAH) market plan acquisitions to improve their brand recognition globally. For instance, in April 2021, Tyvaso was approved by the FDA and released by United Therapeutics to treat pulmonary hypertension associated with interstitial lung disease. It is the first and only therapy available to Americans with PH-ILD, a dangerous, life-threatening condition that could affect more than 30,000 people.

𝐑𝐞𝐜𝐞𝐧𝐭 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭:

September 2021: For $11 billion, the Merck Group, a multinational scientific and technology corporation with headquarters in Germany focused on life sciences and healthcare, purchased Acceleron Pharma. In addition to elevating Merck to the top of the list of businesses specializing in rare diseases, this acquisition will give the corporation control of Acceleron's portfolio of treatments for rare diseases, including etanercept, a Phase III PAH drug.

𝐋𝐢𝐬𝐭 𝐨𝐟 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐏𝐫𝐨𝐟𝐢𝐥𝐞𝐝 𝐢𝐧 𝐭𝐡𝐞 𝐑𝐞𝐩𝐨𝐫𝐭

• United Therapeutics Corporation
• Bayer; Gilead Sciences, Inc.
• Johnson & Johnson
• Viatris Inc.
• GlaxoSmithKline
• Sandoz Inc. (Novartis)
• Lupin Pharmaceuticals, Inc.
• Sun Pharmaceutical Industries, Inc.
• Teva Pharmaceuticals Inc.

𝐅𝐮𝐫𝐭𝐡𝐞𝐫 𝐑𝐞𝐩𝐨𝐫𝐭 𝐅𝐢𝐧𝐝𝐢𝐧𝐠𝐬

• The market in North America is expected to gain a huge portion of the global pulmonary arterial hypertension (PAH) market share in the coming years due to important parties' expanding tactical alliances and partnerships.

• Furthermore, Mannkind had to conduct the study for United Therapeutics for items not subject to the certification and collaboration agreement, which will help the market grow.

• In the Asia Pacific, the growth in this region is primarily driven by increased collaboration for the development of novel products and a rise in the percentage of patients in cardiogenic shock caused by the increasing prevalence of diseases like HIV.

𝐑𝐞𝐚𝐝 𝐌𝐨𝐫𝐞 𝐍𝐞𝐰𝐬 :

https://www.linkedin.com/pulse/pulmonary-arterial-hypertension-pah-market-reach-usd-109-vasa/?published=t

https://ourclass.mn.co/posts/pulmonary-arterial-hypertension-pah-market-growth-framework-2030

https://synkretic.mn.co/posts/pulmonary-arterial-hypertension-pah-market-future-innovation-strategies-2030

https://wecanchat.mn.co/posts/pulmonary-arterial-hypertension-pah-market-challenges-on-upcoming-trends-2030

https://beranda.mn.co/posts/pulmonary-arterial-hypertension-pah-market-scope-emerging-trends-and-high-growth-rate

https://janjaonline.mn.co/posts/pulmonary-arterial-hypertension-pah-market-qualitative-insights-on-application-2030

https://stemfemmes.mn.co/posts/pulmonary-arterial-hypertension-pah-market-highlights-on-future-development-2030

https://markettrendsdotin.wordpress.com/2023/03/14/pulmonary-arterial-hypertension-pah-market-detailed-study-analysis-with-forecast-by-2030/

https://medium.com/@sandra_85356/pulmonary-arterial-hypertension-pah-market-scope-and-opportunities-analysis-2023-2030-aa9bdf668a2c

https://www.homify.co.uk/ideabooks/9310576/pulmonary-arterial-hypertension-pah-market-segmentation-detailed-study-with-forecast-to-2030

https://www.vingle.net/posts/5512781

https://justpaste.it/5in95

https://pastelink.net/d86i7hcx

https://www.evernote.com/shard/s410/sh/f1452b9f-ad20-0ec2-e193-2e5cdbecf729/O832FefvdlmN6ByEmHcJo7-HJMYbucQJzs0E8zFYmZVCIVuzTq5URMbHMw

https://onmogul.com/stories/pulmonary-arterial-hypertension-pah-market-drivers-end-user-key-players-and-challenges-by-2030

https://www.findit.com/imhuropllouacvm/RightNow/pulmonary-arterial-hypertension-pah-market-sharee/74fe5b89-e7fa-45b6-855f-709381b1577e

https://markettrends.hashnode.dev/pulmonary-arterial-hypertension-pah-market-insights-by-growth-emerging-trends-and-forecast-by-2030

https://www.reddit.com/user/Material-World6244/comments/11r3wmj/pulmonary_arterial_hypertension_pah_market_share/

https://gab.com/sandrak1/posts/110021460607269658

https://uberant.com/article/1904473-pulmonary-arterial-hypertension-pah-market-sluggish-growth-rate-foreseen-by-2023-2030/

https://www.diigo.com/item/note/9wuh3/01ku?k=410c0a8ffe094231e160e006d56871ee

https://posteezy.com/pulmonary-arterial-hypertension-pah-market-revenue-growth-opportunities-and-dynamic-business-2030

https://www.zupyak.com/p/3543365/t/pulmonary-arterial-hypertension-pah-market-key-players-end-user-demand-and-analysis-growth-trends-by-2030

https://www.xing.com/discover/detail-activities/6725994595.9821f1?trackingTokens=disco.module.me-feed%3A97e5fd71c25e11edbf7846f875b8784f%3A0.6725994595.activities_activity

https://blogfreely.net/sandrak1/pulmonary-arterial-hypertension-pah-market-size-analytical-overview-growth

https://www.pearltrees.com/sandrak1/item506421607

https://www.bookmarkrush.com/story/pulmonary-arterial-hypertension-pah-market-to-register-unwavering-growth-during-2030/

https://bookmarkfrog.com/story/pulmonary-arterial-hypertension-pah-market-foreseen-to-grow-exponentially-over-2030/

https://www.bookmarkrocket.com/story/pulmonary-arterial-hypertension-pah-market-rising-trends-demand-scope-size-by-2030/

https://demo.sngine.com/blogs/190859/Pulmonary-Arterial-Hypertension-PAH-Market-to-Surge-at-a-Robust

https://www.benedeek.com/blogs/43636/Pulmonary-Arterial-Hypertension-PAH-Market-EvolvingPulmonary-Arterial-Hypertension-PAH-Market

https://www.gift-me.net/blogs/26833/Pulmonary-Arterial-Hypertension-PAH-Market-Rising-Trends-Business-Strategies-and

https://connect.rhabits.io/blogs/223921/Pulmonary-Arterial-Hypertension-PAH-Market-Overview-and-Regional-Outlook-Study

https://www.dr-ay.com/blogs/61018/Pulmonary-Arterial-Hypertension-PAH-Market-Share-Analysis-by-Capacity-Production

https://www.nasseej.net/blogs/28695/Pulmonary-Arterial-Hypertension-PAH-Market-Size-Type-Share-Demand-Drives

http://wwfanclub.com/blogs/183232/Pulmonary-Arterial-Hypertension-PAH-Market-Size-Estimated-to-Observe-Significant

https://www.login.ps/blogs/26983/Pulmonary-Arterial-Hypertension-PAH-Market-to-Witness-Widespread-Expansion-During

https://www.tamaiaz.com/blogs/37115/Pulmonary-Arterial-Hypertension-PAH-Market-Overview-Share-Top-Trends-Growth

https://heroes.app/blogs/232872/Pulmonary-Arterial-Hypertension-PAH-Market-to-Register-a-Stout-Growth

https://www.exoltech.net/blogs/52364/Pulmonary-Arterial-Hypertension-PAH-Market-Report-Includes-Dynamics-Products-and

https://gemawiraclub.com/blogs/7548/Pulmonary-Arterial-Hypertension-PAH-Market-New-Era-Of-Industry-Forecast

https://social.studentb.eu/read-blog/75885

https://kyourc.com/read-blog/67243

https://yruz.one/blogs/19562/Pulmonary-Arterial-Hypertension-PAH-Market-Analysis-Revenue-Price-Share-Growth

https://moniispace.com/read-blog/22787

http://eteria.net/read-blog/23041

https://hissme.com/read-blog/53371

https://cryptofriender.com/read-blog/3939

https://www.vkay.net/read-blog/4927

https://socialblast.club/read-blog/3687

https://legalledger.in/read-blog/13528

https://talkin.co.ke/read-blog/6186

https://baitk.com/read-blog/7162

https://www.pickmemo.com/read-blog/132901

https://stompster.com/read-blog/108349

https://makenix.com/read-blog/25641

https://omiyou.com/read-blog/22984

https://famenest.com/read-blog/27547

https://vherso.com/read-blog/39212

About Us
Markets N Research team is comprised of well skilled and equipped personnel ready to concur any upcoming challenges in the market sector for both individual people and organization around the world. We know time is money, and therefore we ensure we solve your problem within the shortest time possible to prevent delays or missing any opportunities. We use globally accepted techniques with a little innovation from our staff in solving all your market research related challenges.

Contact:
Markets N Research
1016 W Jackson Blvd,
Chicago, IL 60607,
United States
Email - sales@marketsnresearch.com
Tel: +1 773-649-1529

This release was published on openPR.